Current approaches to HCV infection in current and former injection drug users

Journal of Addictive Diseases

Volumn 27, Issue 2, 2008, Pages 25-35

  Grebely, Jason ^a,b   Devlaming, Stanley ^a   Duncan, Fiona ^a   Viljoen, Mark ^a   Conway, Brian ^a,b  

^a VANCOUVER COASTAL HEALTH   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Directly observed therapy; Hepatitis C virus; Injection drug users

Indexed keywords

ALANINE AMINOTRANSFERASE; ILLICIT DRUG; METHADONE; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; INTERFERON;

DRUG DEPENDENCE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PATIENT COMPLIANCE; PRESCRIPTION; REVIEW; RISK FACTOR; TREATMENT RESPONSE; VIRUS TRANSMISSION; PATIENT CARE; RECURRENT DISEASE; SUBSTANCE ABUSE;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERONS; PATIENT CARE TEAM; RECURRENCE; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 52049088979     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v27n02_04     Document Type: Review

References (83)

1. Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol 2000; 14:575-80.
2. Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate. Hepatology 2005; 42(S1):213A-Abstract 44.
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-67.
4. Remis R, et al. Estimating the number of blood transfusion recipients infected by hepatitis C virus in Canada, 1960-1985 and 1990-1992, Health Canada, 1998.
5. van Ameijden EJ, Coutinho RA. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS 1998; 12:625-33.
6. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655-61.
7. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74:212-20.
8. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26:62S-65S.
9. Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, Strathdee SA, Currie SL, Schechter MT, O'Shaughnessy MV. Incidence of hepatitis C virus infection among injection drug users during an outbreak ofHIV infection. CMAJ 2001; 165:889-95.
10. Grebely J, Raffa J, Lai C, Krajden M, Kerr T, Tyndall M. Natural history of hepatitis C virus infection among injection users in Vancouver, Canada. Hepatology 2005; 42:230A-Abstract 87.
11. Wood E, Kerr T, Stoltz J, Qui Z, Zhang R, Montaner JS, Tyndall MW. Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility. Public Health 2005; 119:1111-5.
12. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9:383-98, vi.
13. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
14. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19 Suppl 1:57-65.
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
17. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003; 7:261-87.
18. Sherman M, Villeneuve J-P, et al. Management of Viral Hepatitis: A Canadian Consensus Conference, Toronto, 2004.
19. Reimer J, Schulte B, Castells X, Schafer I, Polywka S, Hedrich D, Wiessing L, Haasen C, Backmund M, Krausz M. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European union countries. Clin Infect Dis 2005; 40 Suppl 5:S373-8.
20. Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005; 40 Suppl 5:S325-9.
21. Strathdee SA, Latka M, Campbell J, O'Driscoll PT, Golub ET, Kapadia F, Pollini RA, Garfein RS, Thomas DL, Hagan H. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40 Suppl 5:S304-12.
22. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005; 40 Suppl 5:S313-20.
23. Genoway K, Grebely J, Duncan F, Viljoen M, Khara M, Raffa J, Tyndall M, DeVlaming S and Conway B. Initiation of Hepatitis C Virus (HCV) Treatment among Injection Drug Users (IDUs). In: Program and Abstracts from the 17th Annual International Conference on the Reduction of Drug Related Harm 2006.
24. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29:159-65.
25. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98:2281-8.
26. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 2005; 40 Suppl 5:S339-45.
27. Taylor LE. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis 2005; 40 Suppl 5:S355-61.
28. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34:188-93.
29. Neri S, Bruno CM, Abate G, Ierna D, Mauceri B, Cilio D, Bordonaro F, Pulvirenti D, Italiano C, Caruso L. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002; 24:1627-35.
30. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40:120-4.
31. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K. Adherence and mental side effects during hepatitis C treatment with inter-feron alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-51.
32. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40 Suppl 5:S336-8.
33. Grebely J, Raffa JD, Meagher C, Duncan F, Genoway KA, Khara M, McLean M, Mead A, Viljoen M, deVlaming S, Fraser C, Conway B. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007; 22:1519-25.
34. Grebely J, Genoway KA, Khara M, Duncan F, Viljoen M, Elliott D, Raffa JD, deVlaming S, Conway B. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18:437-43.
35. Wood E, Schechter MT, Tyndall MW, Montaner JS, O'Shaughnessy MV, Hogg RS. Antiretroviral medication use among injection drug users: two potential futures. AIDS 2000; 14:1229-35.
36. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450-6.
37. Piasecki BA, Lewis JD, Reddy KR, Bellamy SL, Porter SB, Weinrieb RM, Stieritz DD, Chang KM. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 2004; 40:892-9.
38. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34:809-16.
39. Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003; 10:285-93.
40. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179:1254-8.
41. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998; 27:914-9.
42. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, Degott C, Valla D, Erlinger S, Rueff B. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27:1717-22.
43. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, Solinas A, Brouwer JT, Thomas H, Realdi G, Corrocher R, Schalm SW. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27:201-5.
44. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-801.
45. Manns MP. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin North Am 2004; 33:S11-24.
46. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-80.
47. Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, Ito S, Fujiwara K. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91:1374-9.
48. Brau N. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy. J Antimicrob Chemother 2005; 56:991-5.
49. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000; 119:1385-96.
50. Bressler, BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38:639-44.
51. Foster G, Fried MW, Hadziyannis SJ, Chaneac M. Treatment of chronic hepatitis C with peginterferon alfa-2a (40 kD) (Pegasys) and ribavirin (Copegus): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response. Hepatology 2003; 38:246A-Abstract 189.
52. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
53. Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P, McHutchison JG. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000; 7:196-202.
54. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, and Tyndall MW. High prevalence of hepatitis c virus (HCV) genotype 3 infection among injection drug users (IDUs) in Vancouver, Canada. In: Program and Abstracts from the 41st Annual Meeting of the European Association for the Study of the Liver 2006.
55. van Asten L, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Boufassa F, Rezza G, Broers B, Robertson JR, Brettle RP, McMenamin J, Prins M, Cochrane A, Simmonds P, Coutinho RA, Bruisten S. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis 2004; 189:292-302.
56. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeaux D. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995; 171:1607-10.
57. Bourliere M, Barberin JM, Rotily M, Guagliardo V, Portal I, Lecomte L, Benali S, Boustiere C, Perrier H, Jullien M, Lambot G, Loyer R, LeBars O, Daniel R, Khiri H, Halfon P. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat 2002; 9:62-70.
58. Altamirano M, Delaney A, Wong A, Marostenmaki J, Pi D. Identification of hepatitis C virus genotypes among hospitalized patients in British Columbia, Canada. J Infect Dis 1995; 171:1034-8.
59. Chaudhary R, Tepper M, Eisaadany S, Gully PR. Distribution of hepatitis C virus (HCV) genotypes in Canada: results from the LCDC Sentinel Health Unit Surveillance System. Can J Infect Dis 1999; 10:53-56.
60. Grebely J, Conway B, Raffa J, Lai C, Krajden M and Tyndall MW. Uptake of hepatitis C virus (HCV) treatment among injection drug users (IDUs) in Vancouver, Canada. In: Program and Abstracts from the 41st Annual Meeting of the European Association for the Study of the Liver 2006.
61. NCHECR. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2003. Sydney: National Centre in HIV Epidemiology and Clinical Research (NCHECR), The University of New South Wales; 2003.
62. Genoway K, Grebely J, Raffa J, Duncan F, Viljoen M, deVlaming S, Khara M, Tyndall M, Conway B. Initiation of hepatitis C virus (HCV) treatment among injection drug users (IDUs) [Abstract We. 142P]. Paper presented at Program and Abstracts of the 17th International Conference on the Reduction of Drug Related Harm, Vancouver, Canada, 2006.
63. Duncan F, Grebely J, Genoway K, Viljoen M, Khara M, Raffa J, Tyndall MW, DeVlaming S, Conway B. Barriers associated with the initiation of HCV treatment in injection drug users (IDUs): an opportunity for optimizing outcome in marginalized populations. Paper presented at Programs and Abstracts of the 6th HEP DART Conference-Frontiers in Drug Development for Viral Hepatitis, Kohala Coast, Big Island, Hawaii, 2005.
64. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97-100.
65. Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr 2004; 37:1367-75.
66. Restrepo A, Johnson TC, Widjaja D, Yarmus L, Meyer K,Clain DJ, Bodenheimer HC, Min AD. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat 2005; 12:86-90.
67. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288-92.
68. Thompson VV, Ragland KE, Hall CS, Morgan M, Bangsberg DR. Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. AIDS 2005; 19 Suppl 3: S208-S214.
69. Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995; 7:165-8.
70. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8:45-9.
71. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004; 99:1167-75.
72. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67:117-23.
73. Conway B, Prasad J, Reynolds R, Farley J, Jones M, Jutha S, Smith N, Mead A, DeVlaming S. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis 2004; 38 Suppl 5:S402-8.
74. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, Heinz A, van Boemmel F, Berg T. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42:793-8.
75. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345:215-7.
76. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, Cao A, Farci P. Hepatitis C virus in multiple episodes of acute hepatitis in poly-transfused thalassaemic children. Lancet 1994; 343: 388-90.
77. Tisone G, Baiocchi L, Orlando G, Palmieri GP, Pisani F, Rapicetta M, Strati F, Anselmo A, Torri E, Bellanova G, Casciani CU, Angelico M. Hepatitis C reinfection after liver transplantation in relation to virus genotype. Transplant Proc 1999; 31:490-1.
78. Proust B, Dubois F, Bacq Y, Le Pogam S, Rogez S, Levillain R, Goudeau A. Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol 2000; 38:3125-7.
79. Wyatt CA, Andrus L, Brotman B, Huang F, Lee DH, Prince AM. Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasi-species in reinfection. J Virol 1998; 72:1725-30.
80. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258:135-40.
81. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL. Protection against persistence of hepatitis C. Lancet 2002; 359:1478-83.
82. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39:1540-3.
83. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. Hepatology 2006; 44:1139-45.